Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

This study is testing a combination treatment for a type of acute myeloid leukemia (AML) — a blood cancer — in patients whose cancer carries a specific gene mutation called IDH1. The treatment combines a drug called olutasidenib (which targets the IDH1 mutation) with azacitidine (a chemotherapy drug), followed by olutasidenib alone as maintenance therapy. It is specifically for patients who have already responded well to their first treatment. **You may be eligible if...** - You have been diagnosed with AML (not the rare APL subtype) with a confirmed IDH1-R132 mutation - You achieved a complete remission after your first-line treatment with venetoclax plus a hypomethylating agent (a specific combination therapy) - You are 18 or older and in good enough overall health **You may NOT be eligible if...** - Your AML does not have the IDH1-R132 mutation - You did not achieve complete remission after first-line treatment - You have the APL (acute promyelocytic leukemia) subtype with the t(15;17) translocation - You have serious organ problems or active infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.